Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00399711 · ClinicalTrials.gov registry record · Phase 3
Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 560
- Enrollment target
NCT00399711 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 560 participants.
The verdict
NCT00399711, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 560 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). This trial compares the changes in HbA1c after 26 weeks of repaglinide and metformin fixed dose combination tablet given as twice daily versus three times daily regimens or versus twice daily rosiglitazone and metformin fixed dose combination tablet in subjects with type 2 diabetes currently on monotherapy.
Interventions
- DRUG repaglinide and metformin combination tablet
- DRUG rosiglitazone and metformin combination tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 560 participants |
| Start Date | 2006-11 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00399711
The ClinicalTrials.gov registry entry for NCT00399711 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 560 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which repaglinide and metformin combination tablet is the first listed.
NCT00399711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00399711 about?
NCT00399711 is a clinical study titled "Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes". This trial is conducted in the United States of America (USA). This trial compares the changes in HbA1c after 26 weeks of repaglinide and metformin fixed dose combination tablet given as twice daily versus three times daily regimens or versus twice daily rosiglitazone and metformin fixed dose combin...
What is the current status of trial NCT00399711?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 560 participants. The study started on 2006-11. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00399711?
The interventions under investigation include: repaglinide and metformin combination tablet (DRUG), rosiglitazone and metformin combination tablet (DRUG).
Who is sponsoring clinical trial NCT00399711?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.